Graham Defries is a partner in the firm’s Life Sciences group. Mr. Defries advises biotech companies, pharmaceutical companies and investors in the life science sector on private equity and venture capital investments/exits, M&A, corporate finance and collaboration/licensing transactions. In addition to his work for life science companies and investors, he has a particular interest in transactions in the media, technology and insurance sectors.

Mr. Defries has been ranked for life sciences in the 2018 edition of Chambers UK, where clients said he was “outstanding” and “helps keep the focus on the relevant details.” He has been described as “very pragmatic, business savvy and detail oriented” in Chambers UK, 2017. Mr. Defries was recommended for M&A and noted for pharmaceuticals, biotechnology and private equity work in The Legal 500 UK, 2016 and was acknowledged as a “consummate legal adviser” who “protects your interests with panache.” He has been recommended for life sciences in Chambers UK, 2016 and 2015, with a client describing him as “practical, decisive and not one to flap.” He has also been praised for “his co-ordination of a deal” and that he “did an excellent job in aligning all the parties.” In The Legal 500 UK, 2015, he was cited as “brilliant,” a “strong negotiator” and “gets the deal done” with respect to M&A and private equity work and was mentioned for his work in pharmaceuticals and biotechnology. He was also recognised in Chambers UK, 2014 and The Legal 500 UK, 2014 and 2013. In Chambers UK, 2013, Mr. Defries was described as “an M&A lawyer first and foremost” who has “a great deal of experience within the life sciences industry and a strong focus on licensing agreements and collaborations.” Chambers UK, 2012 praised him as “a highly skilled cross-border M&A lawyer with an increasingly active profile in the life sciences sector. Clients say he is smart, business-savvy and a top negotiator.” He has also been mentioned in The Legal 500 EMEA for telecommunications work and in The Legal 500 UK, 2011.

Prior to joining Goodwin in 2018, Mr. Defries was the head of the London life sciences practice at Dechert LLP.

Areas of Practice
Domaines D’Expertise





  • Representing the lead investors BioDiscovery 5 PFCI (advised by Andera Partners) and Canaan XI L.P. (advised by Canaan Partners XI LLC) on the £10 million series A equity financing round of Grey Wolf Therapeutics Limited.*
  • Representing the lead investor LSP Health Economics Fund 2 (advised by Life Science Partners) on the $28 million series C equity financing round of Lumeon Limited.
  • Advising Exscientia Limited (an AI-driven drug discovery company) on its $26 million series B equity financing round. The Investors were Celgene Corporation, GT Healthcare Capital Partners and Evotec AG. 
  • Staten Biotechnology B.V. on its strategic collaboration with Novo Nordisk A/S to develop novel therapeutics for the treatment of triglyceride dyslipidemia, by way of an option to acquire structure.
  • Advising Gadeta on its strategic collaboration with Kite (a Gilead company) to develop novel gamma delta TCR therapies for the treatment of various cancers, by way of an option to acquire structure.
  • Representing the new investors BioDiscovery 5 PFCI (advised by Andera Partners) and LSP 6 Cooperatief UA (Life Science Partners) on the £65 million Series B equity financing round of Artios Pharma Limited
  • Prexton Therapeutics B.V. and its selling shareholders, including M Ventures, in its sale to global pharmaceutical company H. Lundbeck A/S for up to €905 million.*
  • Biocon Limited, Asia’s premier biopharmaceutical company, in the negotiation of an exclusive global collaboration agreement with Sandoz, a Novartis division, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.*
  • The shareholders on the sale of Stat-Dx, a privately owned Spanish diagnostics company, to QIAGEN N.V., for $191 million (including milestones).*
  • Bicycle Therapeutics Limited on its £40 million Series B equity financing round, led by Vertex Global Fund I alongside Cambridge Innovation Capital and Longwood Fund, with existing investors including Novartis Venture Fund, SR One and SVLS also participating in the round.*
  • The selling shareholders in Ziarco Group Limited in connection with the sale of the company to Novartis.*
  • Cellnovo, an innovative biotechnology company, on its IPO in compartment C of the Euronext regulated market in Paris, raising €31.56 million through capital increase, with a market capitalization of €113.6 million.*
  • Egalet, a fully integrated specialty pharmaceutical company, on its IPO on NASDAQ, which raised $54.8 million.*
  • The shareholders of AM-Pharma B.V. on the sale of a minority interest in the company to Pfizer Inc. and the grant of an exclusive option to Pfizer to acquire the remaining equity in the company, exercisable upon completion of a Phase II trial of recAP in the treatment of acute kidney injury related to sepsis, for an upfront payment of $87.5 million and additional potential payments of up to $512.5 million upon option exercise and potential launch of any product by Pfizer.XO1 Limited on its sale to Janssen Pharmaceuticals, Inc. ( an affiliate of Johnson & Johnson).*
  • XO1 is a UK-based company developing Ichorcumab, a novel anticoagulant to treat Thrombosis.*
  • The shareholders of biopharmaceutical company Covagen AG in relation to the sale of Covagen to the Janssen Pharmaceutical Companies of Johnson & Johnson.*
  • ProFibrix B.V. in connection with its sale (by way of an option agreement) to Nasdaq-listed The Medicines Company.*
  • UK-based life sciences company Funxional Therapeutics Ltd. on the sale to Boehringer Ingelheim, the German pharmaceuticals company, of the global rights to its FX125L compound and somatotaxin programme, used to treat a broad range of inflammatory diseases.*
  • Cellzome, Inc. the leading proteomics technologies R&D company with laboratories in the UK and Germany, in connection with its $99 million sale to GlaxoSmithKline plc.*
  • PanGenetics BV and its selling shareholders in connection with the sale for $190 million of a chronic pain compound (PG110) to Abbott Laboratories pursuant to a Dutch/ UK demerger process.*
  • Biocon, India’s leading biotechnology company, in its strategic global agreement with Pfizer, Inc. for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin analog products, for an up-front fee of $200 million and milestone payments of $150 million.*
  • A consortium led by Edmond de Rothschild Investment Partners in a £30 million Series B financing round for Cellnovo Limited, the developer of the first mobile diabetes management system.*
  • The €4.4 billion buyout by Access Industries and The Chatterjee Group of Basell NV.*
  • Advising Capital Z Partners in connection with the buyout of Prestige Insurance Holdings Limited.
  • Centaur Media plc, a listed company which owns The Lawyer magazine, on the sale of Home Interest and the acquisition of MarketMakers Incorporated Limited.*
  • Highland Capital Partners, Index Ventures, HarbourVest Partners and Insight Venture Partners, as the principal investors in Photobox Group, on its announced £400 million acquisition (subject to conditions) by Exponent Private Equity and Electra Partners.*
  • Momondo Group Limited, the operator of the websites “Cheapflights” and “Momondo,” and its shareholders on the sale of a majority interest in Momondo Group to Great Hill Partners, a private equity firm based in Boston, Massachusetts in the U.S.*
  • Index Ventures, Greylock Partners, Redpoint Ventures, SM Trust and Vitruvian Partners (the majority shareholders of leading online takeaway service in relation to the IPO of on the London Stock Exchange’s High Growth segment.*
  • The Mohamed Al Fayed family trust in connection with the sale of Fulham Football Club to Shahid Khan, the CEO of Flex-N-Gate Group and owner of the NFL team, the Jacksonville Jaguars.*
  • The investors (Bessemer Venture Partners, Index Ventures, Idivest Partners and Elaia Partners) of leading global technology company Criteo in connection with its IPO on NASDAQ.*
  • Index Ventures on the $5 billion flotation on NASDAQ of, the UK-based mobile gaming company best known for its hit puzzle game “Candy Crush Saga.”*
  • CBS Corporation on its joint venture to create CBS-branded channels from Chello Zone’s existing entertainment channels across 83 territories worldwide, including Europe, the Middle East, and Africa.*
  • PhotoBox, Europe’s largest online photo processing service, on its £120 million acquisition of Limited, the market leader in online personalised greeting cards.*
  • Altima Partners, as sponsor, and Campos Verdes Ltd. on its $613.2 million business combination with El Tejar SAACEI to form El Tejar Limited, one of the leading agribusinesses in Latin America.*
  • The selling shareholders in Last.FM (including Index Ventures), the leading London-based music and social networking website, in connection with the sale of the company to CBS Corporation for $280 million.*
  • Candover on its €220 million buyout of the high technology optics division of Thales SA.*
  • Capital Z Partners on its $200 million sale of British Marine Holdings.*

* Denotes experience prior to joining Goodwin.

Professional Experience

Mr. Defries serves on the London committee of the Cornwall Community Foundation, a charity which aims to alleviate social deprivation in Cornwall. He is a past chair of the London Advisory Board of Maggie’s Centres, a UK charity which builds and runs centres which offer psychological and emotional support, as well as practical advice, to cancer sufferers.

In The News









College of Law, Guildford
B.A., 1990
Oxford Brookes University



Solicitor of the Senior Courts of England and Wales
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique